ライフサイエンスコーパス: opioid receptor agonist

1 aversion induced by thermal pain or a kappa opioid receptor agonist.

2 ity on the A-ring in its activity as a kappa-opioid receptor agonist.

3 rin A is also the only known non-nitrogenous opioid receptor agonist.

4 2066; spiradoline; 0, 100, 150, or 200 nmol) opioid receptor agonist.

5 e manner with an exogenously administered mu opioid receptor agonist.

6 t is produced by morphine, a preferential mu-opioid-receptor agonist.

7 eported "cocaine-antagonist" effect of kappa-opioid receptor agonists.

8 responses to the prototypical mu- and delta-opioid receptor agonists.

9 of neuropathic pain by morphine and other mu-opioid receptor agonists.

10 dependence issues compared with orthosteric opioid receptor agonists.

11 ter antinociceptive effects of GABA(B) or mu-opioid receptor agonists.

12 nt, selective, and orally bioavailable delta opioid receptor agonists.

13 tification of a novel structural class of mu opioid receptor agonists.

14 y of systemically administered mu, and kappa opioid receptor agonists.

15 lu4]deltorphin II (deltorphin II), a delta 2-opioid receptor agonist (20 micrograms per mouse) twice

16 [D-Pen2,D-Pen5]enkephalin (DPDPE), a delta 1-opioid receptor agonist (20 micrograms per mouse) twice

17 sed an increase of maximal binding of the mu-opioid receptor agonist [3H][d-Ala(2),N-Me-Phe(4),Gly(5)

18 o (DAMGO), kappa (U50488), and Delta (DPDPE) opioid receptor agonists 48 hrs after infection.

19 Kappa opioid receptor agonists acting peripherally had differe

20 Analgesia induced by a kappa opioid receptor agonist administered at the supraspinal

21 ta- ([D-Pen2, D-Pen5]enkephalin- and SNC-80) opioid receptor agonists affected responses to CRD.

22 ng upon their nervous system site of action, opioid receptor agonists alter food consumption, pain pe

23 Morphine, a preferential mu-opioid receptor agonist, alters astroglial development b

24 orin A is the first reported non-nitrogenous opioid receptor agonist and (2) its effects are not medi

25 icacy and safety of a minimally absorbed, mu-opioid receptor agonist and delta-opioid receptor antago

26 ent with mixed opioid effects (mu- and kappa-opioid receptor agonist and delta-opioid receptor antago

27 Buprenorphine, the partial mu-opioid receptor agonist and kappa-, delta-opioid recepto

28 ips between feeding responses produced by mu opioid receptor agonists and melanocortin-3 or 4 (MC-3/4

29 N-Me-Phe4, Gly-ol5]-enkephalin (DAMGO), a mu opioid receptor agonist, and of bicuculline, a GABAA rec

30 ous natural compound known to function as an opioid-receptor agonist, and is undergoing clinical tria

31 Buprenorphine is a mixed opioid receptor agonist-antagonist used clinically for m

32 Opioid receptor agonists are known to alter the activity

33 Selective delta opioid receptor agonists are promising potential therape

34 ly reduced analgesic effects of mu and delta opioid receptor agonists at both spinal and supraspinal

35 groups: a) pentazocine (0.3 mg/kg), a delta-opioid receptor agonist; b) pentazocine pretreated with

36 of this study was to assess a non-selective opioid receptor agonist, biphalin, in decreasing reducin

37 ce on the response to the prototypical kappa-opioid receptor agonist, but decreases responses to the

38 Mice were rendered tolerant to opioid receptor agonists by injecting morphine (20 mg/kg

39 Thus, our results suggest that kappa opioid receptor agonists can exert direct inhibitory act

40 Morphine is a mu-opioid receptor agonist commonly used for pain treatment

41 The opioid receptor agonist D-Ala(2)-N-Me-Phe(4),Gly-ol(5)-e

42 ore ischemic preconditioning or given the mu-opioid receptor agonist D-Ala,2N-Me-Phe,4glycerol5-enkep

43 gically from the nucleus accumbens by the mu-opioid receptor agonist D-Ala-Tyr-Gly-NMePhe-Gly-OH (DAM

44 duced by intra-accumbens injection of the mu-opioid receptor agonist D-Ala2-N-Me-Phe4-gly5-ol-enkepha

45 the spinal cord, brief application of the mu-opioid receptor agonist (D-Ala(2),N-Me-Phe(4),Gly-ol(5))

46 Intrathecal injection of the mu-opioid receptor agonist [D-Ala(2), NMe-Phe(4), Gly-ol(5)

47 which allowed for coadministration of the mu-opioid receptor agonist [D-Ala(2), NMe-Phe(4), Gly-ol(5)

48 hich allowed for co-administration of the mu-opioid receptor agonist [D-Ala(2), NMe-Phe(4), Gly-ol(5)

49 sic and antinociceptive effects of the delta opioid receptor agonist [D-Ala(2),Glu(4)]deltorphin were

50 The antihyperalgesic potency of the mu opioid receptor agonist [D-Ala(2),N-Me-Phe(4),Gly(5)-ol]

51 und that the disinhibitory effects of the mu-opioid receptor agonist [D-Ala2, MePhe4,Gly-(ol)5]-enkep

52 investigated the effects of the selective mu-opioid receptor agonist [D-Ala2-N-Me-Phe4,Gly-ol5]-enkep

53 The delta-opioid receptor agonist [D-Pen2,5]-enkephalin (DPDPE) pr

54 e inhibited by both nociceptin and the delta-opioid receptor agonist, [D-ala2, D-leu5]-enkephalin (DA

55 oiontophoretic application of a selective mu-opioid receptor agonist, [D-Ala2,N-Me-Phe4,Gly5-ol]enkep

56 contrast, application of a selective delta 1-opioid receptor agonist, [D-Pen2,5]enkephalin (DPDPE), r

57 The mu-opioid receptor agonist DAGO reversibly suppressed high-

58 rons responded to bath application of the mu-opioid receptor agonist DAMGO (93%) or the GABA(B) recep

59 erridge observed that an injection of the mu-opioid receptor agonist DAMGO (D-ala(2) -N-Me-Phe(4) -Gl

60 vation through both pathways, whereas the mu opioid receptor agonist DAMGO decreased D2-receptor acti

61 ic inhibition of VTA GABA(A) IPSCs by the mu-opioid receptor agonist DAMGO is significantly reduced i

62 ns, and these IPSCs were inhibited by the mu opioid receptor agonist DAMGO.

63 ced by nucleus accumbens injection of the mu-opioid receptor agonist DAMGO.

64 Administration of mu- and kappa-opioid receptor agonists (DAMGO and U50488H respectively

65 In contrast, treatment with a mu opioid receptor agonist, DAMGO, or a delta opioid recept

66 Low concentrations (< nM) of most opioid receptor agonists decrease the K+ conductance (gK

67 bath-applied met-enkephalin, a nonselective opioid receptor agonist, decreased the number of tetrodo

68 In a phase 2 study of the mixed mu-opioid receptor agonist/delta-opioid receptor antagonist

69 substrates, estrone 3-sulfate and two delta-opioid receptor agonists, deltorphin II, and [D-penicill

70 Recently, a series of mu and delta opioid receptor agonists [dermorphins and deltorphins] a

71 kappa- (U69 593) or delta-selective (DPDPE) opioid receptor agonists did not affect IBa.

72 Here, we demonstrate that delta opioid receptor agonists differentially recruit arrestin

73 tive possibility; whether tolerance of delta opioid receptor agonists (DORs) could be related to agon

74 n contrast, kappa- (U-50,488 and fedotozine) opioid receptor agonists dose-dependently attenuated res

75 has been known for a number of years that mu-opioid receptor agonists (e.g., morphine, beta-endorphin

76 st actions but differ in the nature of their opioid receptor agonist effects; 2a is a predominant MOR

77 nduced by incubating the slices with a micro-opioid receptor agonist (endomorphin-2, 100 nM).

78 This study examined the effects of the kappa opioid receptor agonists fedotozine and U50488H on the a

79 In Experiment 3, increasing doses of the mu-opioid receptor agonist fentanyl (0, 0.0004, 0.004, and

80 is locus also affected sensitivity to the mu-opioid receptor agonist fentanyl.

81 1 (NeuroD) is modulated differentially by mu-opioid receptor agonists; fentanyl increases NeuroD leve

82 Cultures were treated with the selective mu opioid receptor agonist H-Tyr-Pro-Phe (N-Me)-D-Pro-NH2 (

83 Systemically active, nonpeptidic delta opioid receptor agonists have been shown to produce anti

84 While synergistic actions of mu-opioid receptor agonists have been shown, it is unclear

85 Selective, nonpeptidic delta opioid receptor agonists have been the subject of great

86 , but inhibition of Ca2+ channel currents by opioid receptor agonist in dorsal root ganglion cells wa

87 rance to these effects of U-50,488H, a kappa-opioid receptor agonist in mice and rats.

88 tolerance to the analgesic action of delta 2-opioid receptor agonist in the mouse.

89 een found to be a potent and selective kappa opioid receptor agonist in vitro and in vivo.

90 , but not microinjection of the mu- or kappa-opioid receptor agonists in control shRNA-treated animal

91 eptive action of mu- but not kappa- or delta-opioid receptor agonists in mice.

92 gate the clinical utility of kappa and delta-opioid receptor agonists in the peripheral setting.

93 -Phe(4), Gly-ol(5)]-enkephalin (DAMGO), a mu-opioid receptor agonist, in the periacqueductal gray and

94 sex in mediating the larger magnitude of mu-opioid receptor agonist-induced analgesia in male relati

95 Butorphanol (BT), a mixed kappa- and mu-opioid receptor agonist, induces vigorous food intake in

96 Kappa opioid receptor agonists inhibit VTA DA neurons that pro

97 Microinjection of a mu opioid receptor agonist into the BLA resulted in a time

98 following the administration of mu and kappa opioid receptor agonists into the periaqueductal gray ar

99 c, are reduced after local infusion of kappa opioid receptor agonists into the VTA.

100 ining addicted pregnant women on long-acting opioid receptor agonist is the most common strategy to m

101 alkaloid morphine, in addition to being a mu-opioid receptor agonist, is a potent competitive inhibit

102 Coadministration of kappa-opioid receptor agonists (kappa-agonists) with cocaine p

103 kappa-opioid receptor agonists (kappa-ORAs) have been shown to

104 eaves of Salvia divinorum, is a potent kappa-opioid receptor agonist, making it an attractive scaffol

105 ggest these diazaheterocyclic mixed activity opioid receptor agonists may hold potential as new analg

106 ponsiveness to GABAB, but not to delta or mu opioid receptor agonist-mediated analgesia specifically

107 ihyperalgesic and antinociceptive effects of opioid receptor agonists microinjected in the rostral ve

108 elective (DAMGO) and delta-selective (DPDPE) opioid receptor agonists, mimicked the effect of morphin

109 Therefore, by regulating NeuroD activity, mu-opioid receptor agonists modulate the stability of dendr

110 Rats were pretreated with the opioid receptor agonist morphine (1 mg/kg; intraperitone

111 A 5-minute exposure of the myocytes to the opioid receptor agonist morphine protected the myocytes

112 abrogated by systemic administration of the opioid receptor agonist morphine.

113 ha(2)-adrenoceptor agonist clonidine, the mu-opioid receptor agonists morphine and methadone, and the

114 This study focuses on the effect of mu-opioid receptor agonists on CXCR4 signaling in neurons a

115 The complementary action of CB1 and opioid receptor agonists on populations of DRG neurons p

116 as investigated the effect of morphine (a mu-opioid receptor agonist) on the cardiac chronotropic res

117 Both delta 1- and delta 2-opioid receptor agonist, on chronic administration, resu

118 tions since these were not affected by kappa-opioid receptor agonists or antagonists.

119 lgesic and antinociceptive effects of the mu opioid receptor agonist (ORA) [D-Ala(2), NMePhe(4), Gly(

120 It is concluded that mu- and delta-opioid receptor agonists produce a predominantly inhibit

121 Mu-opioid receptor agonists represent mainstays of pain man

122 II (DELT), selective mu, delta1, and delta2 opioid receptor agonists, respectively, in mice selectiv

123 halin (DPDPE) which are mu- kappa- and delta-opioid receptor agonists, respectively, were determined

124 lin (DPDPE), which are mu-, kappa- and delta-opioid receptor agonists, respectively, were determined

125 esigned as conformationally restricted kappa-opioid receptor agonists restricted to the periphery.

126 , multiple injections of delta 1- or delta 2-opioid receptor agonists results in the development of t

127 sion of phasic dopamine release by the kappa-opioid receptor agonist, salvinorin A, supporting a sele

128 stereoenantiomer, d-morphine, an ineffective opioid receptor agonist, significantly reduced LPS- or 1

129 The highly selective delta (delta) opioid receptor agonist SNC 80 [(+)-4- [(alpha R)-alpha-

130 The delta-opioid receptor agonist, SNC 80, did not inhibit PACAP-i

131 is study examined if the delta-opioid (delta-opioid) receptor agonist, SNC-121, can improve retinal f

132 A high-internalizing delta opioid receptor agonist (SNC80) preferentially recruited

133 lls, the potency and maximal effect of delta-opioid receptor agonist (SNC80)-mediated inhibition of f

134 u opioid receptor agonist, DAMGO, or a delta opioid receptor agonist, SNC80, did not prevent angiogen

135 Potent, selective, and efficacious delta-opioid receptor agonists such as (+)-4-[(alphaR)-alpha-(

136 has been demonstrated previously that kappa opioid receptor agonists, such as dynorphin, inhibit oxy

137 In Caenorhabditis elegans, opioid receptor agonists, such as morphine, mimic seroto

138 receptor agonists, endotoxin derivatives, or opioid receptor agonists), suggesting that this phenomen

139 In Caenorhabditis elegans, opioid receptor agonists suppress the overall withdrawal

140 pondingly, in vitro bath application of a mu opioid receptor agonist suppresses the activity of the f

141 cyclase cDNA imparted to dopamine and to mu-opioid receptor agonists the ability to modulate the act

142 a potent, selective, and G protein biased mu opioid receptor agonist, TRV130 ((R)-30).

143 adenosine (200 microM) nor the selective mu-opioid receptor agonist Tyr-D-Ala-Gly-MePhe-Gly-ol (DAMG

144 ocaine (80 microM) or to the kappa-selective opioid receptor agonist U-50,488H (1 microM) displayed a

145 al hypothalamus or administration of a kappa opioid receptor agonist (U-50,488) or antagonist (nor-bi

146 e (threshold-elevating) effects of the kappa-opioid receptor agonist U50,488.

147 hilar pathway were decreased by the kappa(1) opioid receptor agonist U69,593, an effect blocked by th

148 set and recovery from tolerance to the kappa opioid receptor agonist (U69,593) which were measured wi

149 onditioned place aversion (CPA) to the kappa-opioid receptor agonist U69593 (2 x 0.16 mg/kg s.c.).

150 B) agonist baclofen (1 microM) and the kappa-opioid receptor agonist U69593 [(+)-(5alpha,7alpha,8beta

151 Bath application of the kappa opioid receptor agonist U69593 decreased D2-receptor act

152 Methadone is a mu-opioid receptor agonist used for treating opiate depende

153 In addition, an opioid receptor agonist was found to increase the oxLDL

154 TAN-67, a delta1-opioid receptor agonist, was administered 10 or 30 mg/kg

155 the tolerance and physical dependence of mu opioid receptor agonists, we have investigated the possi

156 and experimental evidence from several kappa opioid receptor agonists, we illustrate a "competitive"

157 of VP afferents and their sensitivity to mu opioid receptor agonists, we virally expressed channel r

158 lu4 deltorphin II (deltorphin II), a delta 2-opioid receptor agonist were determined in mice.

159 f activation, while neither delta- nor kappa-opioid receptor agonists were effective in modifying cal

160 Etorphine is an non-selective opioid receptor agonist with very potent analgesic effec

161 differentially affect feeding elicited by mu opioid receptor agonists within the nucleus accumbens sh

162 pe mice, suggesting that G protein biased mu opioid receptor agonists would be more efficacious with